prodchem
Sep 1, 2026
The American Chemistry Council's original outlook for the U.S. chemical industry offered a deceptively simple recovery story: after years of weak performance, chemical production was expected to grow just 0.3% in 2026, before accelerating sharply to 2.3% in 2027.
That forecast, published in late 2025, positioned 2027 as the year when the U.S. chemical industry's long-running downturn would finally give way to a meaningful recovery. ACC economists expected lower interest rates, stronger manufacturing investment, housing activity and favorable policy conditions to gradually improve chemical demand.
But the latest ACC outlook has changed the picture.
In its Mid-Year 2026 Outlook, ACC now expects U.S. chemical production volumes to rise only about 1.5% in 2027, substantially below the original 2.3% forecast. The revision does not eliminate the recovery thesis, but it suggests that the rebound is likely to be slower and more uneven than initially anticipated.
The December 2025 ACC outlook effectively divided the recovery into two stages.
2026: stabilization.
2027: acceleration.
The industry was expected to record only 0.3% volume growth in 2026 after an estimated 0.7% gain in 2025. ACC described this as the continuation of roughly four years of essentially flat chemical production.
Then came the anticipated inflection point: 2.3% growth in 2027.
The forecast was significant because 2.3% would represent a much more meaningful expansion than the industry had experienced during the preceding downcycle.
The original forecast was based on several interconnected economic drivers.
Lower interest rates were expected to improve construction and housing activity. Tax and regulatory changes were expected to encourage domestic investment. Manufacturing investment was expected to strengthen, while the broader U.S. industrial economy was expected to recover from several years of weakness.
Housing was particularly important.
ACC's chief economist pointed out that a typical new U.S. single-family home contains roughly 33,000 pounds of chemistry, including materials used in pipes, insulation, window and door systems, engineered wood, coatings and other construction applications. A housing recovery would therefore generate chemical demand through multiple channels rather than simply through construction materials.
The latest ACC data suggests that the recovery is developing, but not uniformly.
The U.S. chemical industry entered 2026 with weak production momentum. ACC reported that its U.S. Chemical Production Regional Index fell 0.4% in January, leaving production 1.7% below the level of a year earlier.
At the same time, chemical manufacturing investment has remained comparatively strong.
Chemical manufacturing construction spending reached $45.6 billion in January, up 11.5% year over year, demonstrating that companies are still investing even while near-term demand remains constrained.
This creates one of the central contradictions in the current market:
capital investment is recovering faster than chemical production.
That may eventually create stronger domestic capacity and competitiveness, but it does not automatically translate into higher utilization or margins.
The original 0.3% → 2.3% trajectory can now be viewed as a useful benchmark for measuring how quickly the recovery thesis is materializing.
Forecast stage | U.S. chemical production growth |
|---|---|
2025 estimate | 0.7% |
Original 2026 forecast | 0.3% |
Original 2027 forecast | 2.3% |
Latest ACC 2027 outlook | 1.5% |
The most important change is the 0.8 percentage-point reduction in the 2027 growth forecast.
That is not a collapse of the recovery story. It is a shift from an aggressive rebound toward a more moderate normalization.
The recovery is also expected to vary substantially by segment.
In the latest ACC outlook, U.S. basic chemical production is expected to rise 0.6% in 2027, while specialty chemical production is projected to rebound more strongly at 2.7%. Agricultural and consumer chemicals are expected to grow around 2.0% and 2.1%, respectively.
This suggests that the next phase of the recovery may be more valuable for some producers than others.
Commodity chemical producers could continue facing global overcapacity even as domestic demand improves. Specialty chemical producers exposed to semiconductor, data-center, healthcare and other structural-growth markets may have better opportunities to outperform the overall industry.
The contrast is particularly important because specialty chemical demand is increasingly connected to sectors that are receiving structural investment.
ACC expects specialty chemical production to decline slightly in 2026, but then rebound by 2.7% in 2027. The organization specifically highlights specialty chemicals supporting semiconductors, data centers and healthcare as areas expected to continue expanding.
That creates a two-speed recovery:
Traditional commodity chemicals: gradual improvement, constrained by global capacity.
High-value specialty chemicals: potentially faster recovery because of structural demand from advanced manufacturing and technology.
One part of the original ACC thesis remains particularly relevant: the United States continues to benefit from relatively competitive energy and feedstock economics.
ACC argues that the U.S. chemical industry's cost advantage from domestic energy resources should persist. This is especially important for petrochemicals and other energy-intensive chemical processes.
However, a cost advantage does not guarantee strong margins.
If global chemical overcapacity remains high, U.S. producers can have lower production costs while still facing weak selling prices. This is why the recovery in demand and capacity utilization matters as much as the underlying energy advantage.
The U.S. chemical industry's recovery cannot be analyzed in isolation.
Global chemical markets remain burdened by excess capacity, particularly in commodity petrochemicals and polymers. ACC itself has highlighted excess capacity from non-market economies as a major threat to U.S. chemical producers and export competitiveness.
This means stronger U.S. demand could have two opposing effects.
On one side, domestic demand would improve plant utilization and margins.
On the other, producers may continue facing imported competition and aggressive global pricing.
The eventual strength of the recovery will depend on which effect dominates.
The reduction from 2.3% to 1.5% is strategically important because it changes expectations about how quickly chemical producers can return to healthier operating conditions.
A 2.3% expansion would have represented a relatively strong cyclical rebound.
A 1.5% increase is still positive, but it looks more like normalization after a prolonged downturn.
For investors and chemical companies, that distinction matters because capital spending, hiring, inventory planning and plant utilization decisions are often based on expected demand growth several quarters ahead.
The latest data suggests that the U.S. chemical industry should not be treated as one homogeneous market.
Three different recovery paths are emerging:
1. Technology-linked chemicals
Semiconductor and data-center demand is creating pockets of strong growth.
2. Domestic manufacturing-linked chemicals
These could benefit if U.S. industrial investment and reshoring continue.
3. Commodity chemicals
These remain exposed to global overcapacity and international pricing pressure.
This makes the headline 1.5% industry growth forecast less important than where that growth occurs.
From an industry-intelligence perspective, the ACC forecast can now be ranked across five dimensions:
1. Original recovery signal — 2.3% in 2027.
The original forecast identified 2027 as the likely acceleration year.
2. Current recovery signal — 1.5%.
The latest outlook still points toward growth but at a more moderate pace.
3. Capital investment — positive.
Chemical manufacturing construction spending has remained strong despite weak near-term production.
4. Segment divergence — increasing.
Specialty chemicals linked to semiconductors, data centers and healthcare appear better positioned than some traditional commodity segments.
5. Global risk — still elevated.
Excess capacity and weak international pricing remain major constraints on U.S. producers.
The ACC's original 0.3% 2026 → 2.3% 2027 forecast remains useful as a benchmark for understanding how expectations for the U.S. chemical recovery have evolved.
But the latest evidence tells a more cautious story.
ACC still expects U.S. chemical production to accelerate in 2027, yet its latest estimate of approximately 1.5% growth is materially below the original 2.3% projection.
The industry's recovery therefore appears to be delayed rather than cancelled.
For chemical companies, the key question is increasingly not whether U.S. chemical production will recover, but which segments will capture that recovery first. Technology-linked specialties, advanced manufacturing inputs and healthcare-related chemicals may outperform the headline industry number, while commodity producers continue to face the structural challenge of global excess capacity.
That makes the change from 2.3% to 1.5% more than a forecast revision. It is a signal that the U.S. chemical industry's next growth cycle may be slower, more selective and more dependent on high-value end markets than the original 2027 recovery thesis suggested.
Featured Product
Found this useful?
Continue Reading
German petrochemical exporters gain ground as Asian and Middle Eastern supply disruptions create market gaps. Analyze the sustainability of this advantage for global buyers.
China's manufacturing PMI remains below 50, signaling continued contraction. Analyze the impact on petrochemical feedstock demand and global procurement strategies.
Covestro trades near its 52-week high yet margin recovery remains elusive. Analyze why the broader chemical cycle lag impacts investor sentiment and procurement strategies.
